Cahiers Santé Médecine Thérapeutique
MENUAlternative analyses of randomised trials: average gains in life expectancy or event-free time as patient-centred measures of therapeutic benefit Volume 31, issue 1, Janvier-Février 2022
- Key words: clinical trial, hazard ratios, absolute risk reduction, mean survival, event-free time
- DOI : 10.1684/sanmt.2022.121
- Page(s) : 102-7
- Published in: 2022
The impact of randomised controlled trials is highly dependent on the presentation of results.
Objective
Traditionally, the results of randomised controlled trials are presented as relative risk reductions or hazard ratios. These presentations of results are the most favourable to the acceptance and marketing of the drug. In addition to the classic absolute risk reduction, which estimates the number of patients that need to be treated to prevent or most often delay an event (NNT for number needed to treat), an alternative and informative way of presenting the results of randomised controlled trials is to estimate the gain in mean survival or event-free time. Study selection: recent randomised controlled cardiovascular trials that evaluated ezetimibe (IMPROVE-IT), évolocumab (FOURIER) and alirocumab (ODYSSEY OUTCOMES).
Results
Event-free time gains for the primary endpoints ranged from 10 to 35 days over the duration of the studies; mean NNTs ranged from 50 to 67 for delaying any of the composite endpoint events.
Conclusion
publication of survival gains as a complementary measure of treatment effect is probably more useful than relative risk reduction for both patient and physician.